Elevance Health, Inc. (ELV) is a $71.8 billion health benefits company offering insurance and related services, including health, dental, vision, and pharmacy benefits, life insurance, and disability insurance, with a focus on healthcare disparities. ELV, a large-cap stock, leads as the largest Blue Cross Blue Shield provider with 47 million members.

Despite its dominance, ELV stock has dropped 43.2% from its 52-week high, declining 14.5% in the past three months. Long-term, ELV shares fell 12.6% YTD and 42.1% over a year, trading below moving averages since 2024. The underperformance is linked to rising medical costs, a decrease in membership, and regulatory changes.

Following Q2 results, ELV shares closed down over 12%, with an adjusted EPS of $8.84, down 14.2% year-over-year, and revenue of $49.4 billion, up 14.3% from the previous year. Rival UnitedHealth Group’s shares have also lagged behind, dropping 39% YTD and 47.7% over 52 weeks.

Wall Street analysts are optimistic about ELV’s future, with a consensus “Moderate Buy” rating and a mean price target of $357.06, indicating a potential 10.8% upside from current levels.

Read more at Yahoo Finance: Is Elevance Health Stock Underperforming the S&P 500?